Scarica l'app Stockscreener
26.27
1.68%
-0.45
Dopo l'orario di chiusura:
25.79
-0.48
-1.83%
Precedente Chiudi:
$26.72
Aprire:
$26.37
Volume 24 ore:
874.20K
Relative Volume:
0.46
Capitalizzazione di mercato:
$2.73B
Reddito:
$71.78M
Utile/perdita netta:
$-295.28M
Rapporto P/E:
-8.3141
EPS:
-3.1597
Flusso di cassa netto:
$-271.85M
1 W Prestazione:
-3.31%
1M Prestazione:
+12.36%
6M Prestazione:
+63.98%
1 anno Prestazione:
+159.07%
Intervallo 1D:
$25.86
$26.68
Intervallo di 1 settimana:
$25.86
$28.23
Portata 52W:
$8.195
$28.23
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
26.27 | 2.81B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer - Sahm
Edmond DE Rothschild Holding S.A. Invests $2.18 Million in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Deep Track Capital, LP Expands Nurix Therapeutics Inc (NRIX) Sta - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History - Yahoo Finance
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - MarketBeat
Nurix Therapeutics, Inc. Announces Appointment of Wes Burwell to Chief Human Resources Officer - marketscreener.com
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Nurix (NRIX) Results Review: The EPS Result Is Below Expectation for the Current Session; Post-Earnings: Shares Fall 0.88%EPS Growth Rate - Vinanet
Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right? - Sahm
Handelsbanken Fonder AB Buys 86,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche - Sahm
Nurix Therapeutics stock hits 52-week high at $26.40 By Investing.com - Investing.com Nigeria
Nurix Therapeutics stock hits 52-week high at $26.40 - Investing.com
Sei Investments Co. Buys 46,132 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Understanding the Setup: (NRIX) and Scalable Risk - Stock Traders Daily
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
NRIX Maintained by RBC Capital -- Price Target Raised to $36 - GuruFocus
Royal Bank Of Canada Boosts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00 - MarketBeat
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says - marketscreener.com
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $36 - Moomoo
RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating - marketscreener.com
Dimensional Fund Advisors LP Purchases 349,710 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Nurix Therapeutics, Inc. (NRIX): A Biotech Stock with 32% Upside Potential and Strong Buy Ratings - DirectorsTalk Interviews
Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 4,356 Shares of Stock - MarketBeat
Nurix Therapeutics stock hits 52-week high at $25.22 By Investing.com - Investing.com UK
Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins - Yahoo Finance
NRIX (NRIX) holder Hansen details option exercise and 10b5-1 stock sales - Stock Titan
Nurix Therapeutics stock hits 52-week high at $25.22 - Investing.com
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighStill a Buy? - marketbeat.com
Nurix Therapeutics (NRIX) Chief Scientific Officer Gwenn Hansen Sells 4,111 Shares - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,111 Shares - MarketBeat
Houte Hans Van Sells 4,761 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics, Inc. (NRIX) Options Chain - Yahoo! Finance Canada
NRIX (NRIX) holder files to sell 4,761 shares after recent 10b5-1 sales - Stock Titan
NRIX (NASDAQ: NRIX) insider files to sell 4,111 shares and details 10b5-1 trades - stocktitan.net
NRIX Looks 273.5% Overvalued on GF Value™ - GuruFocus
Nurix Therapeutics Gets $10 Million Milestone Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader - marketscreener.com
Nurix Therapeutics (NASDAQ:NRIX) Earns Buy Rating from Needham & Company LLC - marketbeat.com
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader - The Manila Times
Nurix Therapeutics, Inc. Announces $10 Million Milestone Payment Associated with Initiation of A Phase 1 Clinical Trial of A Stat6 Degrader - marketscreener.com
Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial - marketscreener.com
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Form 4 Nurix Therapeutics Inc For: 4 August By Investing.com - Investing.com Nigeria
Nurix Therapeutics chief legal officer Christine Ring sells $382k stock - Investing.com
Roche, Nurix Therapeutics Enroll First Patient in Late-stage Study of Blood Cancer Drug Bexobrutideg - marketscreener.com
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - The Manila Times
Nurix Therapeutics Announces First Patient Enrolled in Phase 3 DAYBreak CLL-306 Study of Bexobrutideg in Relapsed/Refractory CLL/SLL - quiverquant.com
Nurix Therapeutics (NRIX) insider plans $385K sale of stock options and RSUs - stocktitan.net
Nurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care - Stock Titan
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nurix Therapeutics Inc Azioni (NRIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hansen Gwenn | Chief Scientific Officer |
Aug 05 '26 |
Sale |
25.00 |
4,356 |
108,900 |
117,227 |
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):